01460nas a2200373   4500000000100000008004100001260001300042653001500055653001000070653000900080653002200089653002600111653001500137653001000152653001200162653003000174653001100204653002200215653001100237653001200248653000900260653001600269653001300285100001400298700001400312700001200326700001200338700001000350245011900360300000900479490000700488520057700495022001401072       1994                            d  c1994 Nov10aAdolescent10aAdult10aAged10aAged, 80 and over10aAnti-Bacterial Agents10aBangladesh10aChild10aDapsone10aDrug Therapy, Combination10aFemale10aFollow-Up Studies10aHumans10aleprosy10aMale10aMiddle Aged10aRifampin1 aFaruque E1 aHoque A K1 aAhmed J1 aAhmed R1 aAli A00aPaucibacillary leprosy patients treated with multidrug therapy four years experience (1988 to 1991) in Bangladesh.  a95-80 v633 a<p>Two hundred and fifty paucibacillary (PB) leprosy patients were treated with WHO recommended multidrug therapy (MDT) and followed up them for four years. The paucibacillary MDT regimen (PBR) was well accepted and tolerated by the patients. Clinical regression was attained in 60% patients after 6 doses of PBR. Reversal reaction occurred in 14% cases and relapse were found in 1.6% cases 18-24 months after completing the treatment. The incidence of reversal reaction was high in patients with more than 2 thickened nerve trunks associated with more than 5 patches.</p>  a0386-3980